Abstract

During the past 6 years, the technique of renal sympathetic denervation has been proposed as a treatment for drug-resistant hypertension, and several studies have been published that claimed to provide supportive evidence of its efficacy. There is no question that resistant hypertension is a major medical concern: hypertension has been authoritatively designated as the greatest threat to the global burden of disease, and approximately 8% of hypertensive individuals have resistant hypertension. However, the first studies reporting the efficacy of renal sympathetic denervation were not methodologically capable of supporting such claims. Subsequently, in March 2014, the most appropriately designed clinical trial failed to provide supportive evidence of the intervention's efficacy. This Commentary presents a cautionary case study to exemplify the need for optimal methodologic rigor in all experimental clinical research and highlights the pitfalls should claims from less than optimally rigorous studies be afforded more weight than is scientifically appropriate.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.